MW 222.24 Da, Purity >98%. Non-specific cAMP and cGMP inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
Images
Publications
Filter by
- Acta pharmaceutica Sinica. B 12:1899-19122022Disruption of adipocyte HIF-1 improves atherosclerosis through the inhibition of ceramide generation.Applications:Unspecified applicationReactive species:Unspecified reactive speciesPengcheng Wang,Guangyi Zeng,Yu Yan,Song-Yang Zhang,Yongqiang Dong,Yangming Zhang,Xingzhong Zhang,Huiying Liu,Zhipeng Zhang,Changtao Jiang,Yanli PangPubMed 35847503
Key facts
- CAS number
- 28822-58-4
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 222.24 Da
- Molecular formula
- C10H14N4O2
- PubChem identifier
- 3758
- Nature
- Synthetic
Alternative names
5''-cyclic nucleotide phosphodiesterase 1B, 5''-cyclic nucleotide phosphodiesterase 1C, 63 kDa Cam-PDE, A1AR, A1R, A2AAR, A2aR, A3AR, A3R, AA1R_HUMAN, AA2AR_HUMAN, AA2BR_HUMAN, AA3R_HUMAN, AD 026, ADENO, ADORA 1, ADORA 2, ADORA 3, ADORA2A, ARA3, Adenosine A2 receptor, Adenosine A2a receptor, Adenosine A3 receptor, Adenosine receptor A1, Adenosine receptor A2a, Adenosine receptor A2b, Adenosine receptor A3, Adenosine receptor subtype A2a, Calcium/Calmodulin stimulated cyclic nucleotide phosphodiesterase, Calcium/calmodulin dependent 3' 5' cyclic nucleotide Phosphodiesterase 1B, Calcium/calmodulin dependent 3'5' cyclic nucleotide phosphodiesterase 1C, Calcium/calmodulin-dependent 3'', Calmodulin stimulated phosphodiesterase PDE1B1, Cam-PDE 1B, Cam-PDE 1C, EIEE6, FEB3, FEB3A, FHM3, GEFS+2, GEFSP2, GPCR 2, HBSC I, HBSC II, HGNC:264, HSPDE1C1A, Human 3'5' cyclic nucleotide Phosphodiesterase, NAC3, Nav 1.1, Nav1.3, Netrin 1 receptor, PDE1B1, PDE1B_HUMAN, PDE1C_HUMAN, PDES 1B, Phosphodiesterase 1B, Phosphodiesterase 1B calmodulin dependent, Phosphodiesterase 1C, Phosphodiesterase 1C calmodulin dependent, Phosphodiesterase 1C calmodulin dependent 70kDa, Presumed 63kDa form of the type 1 cyclic nucleotide phosphodiesterase family known as PDE1B, RBI, RDC 7, RDC 8, RP11 552M11.7, Ri, SCN1, SCN1A_HUMAN, SCN2A1, SCN2A2, SCN2A_HUMAN, SCN3A_HUMAN, SMEI, Sodium channel protein brain I alpha subunit, Sodium channel protein brain I subunit alpha, Sodium channel protein brain II subunit alpha, Sodium channel protein brain III subunit alpha, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha, Sodium channel protein type I subunit alpha, Sodium channel protein type II subunit alpha, Sodium channel protein type III subunit alpha, Sodium channel voltage gated type 1 alpha subunit, Sodium channel voltage gated type I alpha polypeptide, TGPCR1, Voltage-gated sodium channel subtype III, Voltage-gated sodium channel subunit alpha Nav1.1, Voltage-gated sodium channel subunit alpha Nav1.2, Voltage-gated sodium channel subunit alpha Nav1.3, adora 2b, bA552M11.5, brain III voltage-gated sodium channel, brain sodium channel type I, hA2aR, hCam-3, sodium channel, brain type III, alpha subunit, sodium channel, neuronal type III, alpha subunit, sodium channel, voltage-gated, type III, alpha polypeptide, sodium channel, voltage-gated, type III, alpha subunit
Recommended products
MW 222.24 Da, Purity >98%. Non-specific cAMP and cGMP inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
Key facts
- CAS number
- 28822-58-4
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 222.24 Da
- Molecular formula
- C10H14N4O2
- PubChem identifier
- 3758
- Nature
- Synthetic
- Solubility
Soluble in DMSO to 75 mM.
Soluble in ethanol to 50 mM.
- Biochemical name
- 3-Isobutyl-1-methylxanthine
- Biological description
Non-specific cAMP and cGMP inhibitor
- Canonical SMILES
- CC(C)CN1C2=C(C(=O)N(C1=O)C)NC=N2
- InChI
- InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
- InChIKey
- APIXJSLKIYYUKG-UHFFFAOYSA-N
- IUPAC name
- 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
- Storage information
- Store under desiccating conditions, The product can be stored for up to 12 months
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Adenosine A1 Receptor also called ADORA1 alongside its counterparts adenosine receptors A2a (ADORA2A) A2b (ADORA2B) and A3 (A3AR) and the phosphodiesterases PDE1B and PDE1C along with sodium channels SCN1A SCN2A and SCN3A play a significant role in signal transduction. These receptors and enzymes interact with cAMP and cGMP molecules to modulate cellular responses while the sodium channels particularly Scn1a mediate electrical signaling in nerve cells. The molecular weight of many of these proteins varies widely for instance ADORA1 has an approximate mass of 37 kDa. These proteins are highly expressed in tissues such as the brain and heart contributing to diverse physiological processes.
- Biological function summary
These proteins and receptors are integral to several cellular functions. For example adenosine receptors participate in the regulation of neurotransmitter release and cardiovascular functions. PDE1B and PDE1C hydrolyze cAMP and cGMP critical secondary messengers that influence vascular tone and neuronal signaling. Meanwhile sodium channels like SCN1A form parts of voltage-gated sodium channel complexes that are key for action potential generation and propagation in neurons.
- Pathways
These proteins and receptors are incorporated into critical signaling routes. Adenosine receptors and phosphodiesterases are involved in G protein-coupled receptor signaling and cAMP-dependent pathways highlighting their role in maintaining cellular homeostasis and response to external stimuli. Sodium channels SCN1A SCN2A and SCN3A are prominent in pathways governing nervous system excitability and conductance with interconnected proteins including other channels and kinases that modulate neuronal activities.
- Associated diseases and disorders
These protein targets relate strongly to neurological and cardiovascular conditions. For instance mutations in SCN1A are closely linked to epilepsy while dysregulation in adenosine receptor signaling can contribute to arrhythmias or heart failure. The phosphodiesterase inhibitors including compounds like IBMX (isobutylmethylxanthine) affect cAMP and cGMP pathways and can overlap with therapeutic interventions targeting these disorders. These associations highlight the need for precise modulation of their activity to mitigate disease effects.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Chemical Structure - IBMX, Non-specific cAMP and cGMP inhibitor (ab120840)
2D chemical structure image of ab120840, IBMX, Non-specific cAMP and cGMP inhibitor
Functional Studies - IBMX, Non-specific cAMP and cGMP inhibitor (ab120840)
1e7 3T3-L1 cells were treated for 15 minutes with 1 µM dexamethasone (Dexamethasone, anti-inflammatory glucocorticoid ab120743) and 1 µg x mL-1 insulin (Recombinant human Insulin protein (Active) ab123768) with the addition of 50 µM forskolin (Forskolin, Adenylyl cyclase activator ab120058), 0.5 mM IBMX (ab120840) or 0.1 mM 8-CPT-cAMP (8-(4-Chlorophenylthio)adenosine 3',5'-cyclic monophosphate (8-CPT-cAMP), Cell permeable cAMP analog. ab120424), extracted according to the protocol. Lysates were diluted 50-fold, and tested in duplicates (+/-SD).
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com